Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD)[1].
[1]. Kasper Vadstrup, et al. Anti-NKG2D mAb: A New Treatment for Crohn's Disease• Int J Mol Sci. 2017 Sep 16;18(9):1997.
















